华东医药股份有限公司2024年度股东大会决议公告

Meeting Overview - The shareholder meeting was held on May 15, 2025, from 14:00 to 15:00 at the new building of East China Pharmaceutical Co., Ltd. in Hangzhou, Zhejiang Province [3][4] - The meeting was conducted through a combination of on-site and online voting [4] Attendance - A total of 837 shareholders attended the meeting, representing 1,178,101,216 shares, which is 67.1636% of the total voting shares [5] - Among them, 31 shareholders voted on-site, representing 1,019,862,337 shares (58.1424%), while 806 shareholders voted online, representing 158,238,879 shares (9.0212%) [5][6] - 835 minority shareholders participated, representing 159,163,059 shares (9.0739%) [7] Proposal Voting Results - The following proposals were approved with significant majority votes: - The 2024 Annual Board Work Report received 99.9694% approval [10][11] - The 2024 Annual Supervisory Board Work Report received 99.9696% approval [13][14] - The 2024 Financial Settlement Report received 99.9674% approval [15][16] - The 2024 Annual Report and its summary received 99.9696% approval [17][18] - The 2024 Profit Distribution Plan received 99.9794% approval [19][20] - The reappointment of the accounting firm received 99.6448% approval [22][23] - The proposal for providing guarantees for subsidiaries in 2025 received 99.9741% approval [24][25] - The proposal for expected daily related transactions for 2025 (Yuan Da Group) received 99.9196% approval [26][27] - The proposal for expected daily related transactions for 2025 (other related parties) received 99.9705% approval [28][29] - The authorization for the board to formulate the 2025 interim dividend plan received 99.9812% approval [30][31] Legal Opinion - The legal opinion provided by Zhejiang Tian Ce Law Firm confirmed that the meeting's convening, procedures, and voting were in compliance with legal and regulatory requirements [32]